Immunoglobulin G that interferes with thyroid-stimulating antibody measurements can be eliminated specifically by incubation with synthetic peptides corresponding to partial sequences of the human thyrotropin receptor.
Two IgG preparations out of more than 100 tested, distinct from the typical Graves' disease IgG, were shown specifically to enhance the cAMP production of FRTL-5 cells by the addition of a synthetic peptide, P-218, corresponding to the partial amino acid sequence from No. 354 to 367 of the h thyroid-stimulating hormone (TSH) receptor. IgG obtained from a patient with Graves' disease revealed a serial alteration of the enhancement; negative in July, 1989, potent in January, 1991, and weak in September 1991. During this time there was no remarkable change in the patient's serum protein components or TSH receptor antibody activities. A peptide with a completely reverse sequence of P-218 showed little effect, and P-218 in combination with bTSH or forskolin did not affect cAMP production by these ligands, and did not alter the inhibitory activity of thyroid-stimulation-blocking antibody. High concentrations of P-218 resulted in reduction of such enhancing effects of cAMP by thyroid-stimulating antibody. P-218 affinity chromatography showed almost complete absorption and recovery of thyroid-stimulating antibody and P-218 reactivity. In the 15 synthesized peptides with proximal sequences of P-218 (from 338 to 378), regions thought to be involved with the enhancement were defined as follows: 354-367 (P-218) is a critical unit; 354-357 and 364-367 are considered to be the essential sites; several amino acid extensions on both N- and C-terminal sides of P-218 show additional enhancement. In conclusion, evidence was shown to indicate the presence of IgG that interferes with thyroid-stimulating antibody measurements.
Ueda
Y
Y
Central Research Laboratory, Ishihara Industrial Co, Kusatsu, Japan.
Sugawa
H
H
Akamizu
T
T
Okuda
J
J
Kiho
Y
Y
Mori
T
T
D000595:Amino Acid Sequence; D000596:Amino Acids / Q000032:analysis*; D001323:Autoantibodies / Q000032:analysis* / Q000276:immunology / Q000378:metabolism; D002460:Cell Line; D002846:Chromatography, Affinity; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D006111:Graves Disease / Q000097:blood / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis / Q000276:immunology / Q000502:physiology*; D018828:Immunoglobulins, Thyroid-Stimulating; D008024:Ligands; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000032:analysis / Q000276:immunology / Q000494:pharmacology*; D010455:Peptides / Q000032:analysis / Q000494:pharmacology*; D011863:Radioimmunoassay; D011989:Receptors, Thyrotropin / Q000032:analysis* / Q000276:immunology; D017386:Sequence Homology, Amino Acid; D013961:Thyroid Gland / Q000166:cytology / Q000378:metabolism / Q000648:ultrastructure; D013972:Thyrotropin / Q000494:pharmacology
D000596:Amino Acids; D001323:Autoantibodies; D007074:Immunoglobulin G; D018828:Immunoglobulins, Thyroid-Stimulating; D008024:Ligands; D010446:Peptide Fragments; D010455:Peptides; D011989:Receptors, Thyrotropin; D005576:Colforsin; D013972:Thyrotropin; D000242:Cyclic AMP